Search results
Showing 1291 to 1305 of 2107 results for technology appraisal
Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.
View recommendations for TA373Show all sections
Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.
Show all sections
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]
In development Reference number: GID-TA11678 Expected publication date: 19 August 2026
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)
This guidance has been updated and replaced by NICE's technology appraisal guidance on sodium zirconium cyclosilicate for treating hyperkalaemia (TA1148).
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.
Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery (TA170)
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement in adults.
View recommendations for TA170Show all sections
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.
View recommendations for HTG575Show all sections
This guidance has been replaced by NICE technology appraisal guidance 69.
Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)
This guidance has been replaced by NICE technology appraisal guidance 323.
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA196)
This guidance has been replaced by NICE technology appraisal guidance 326.
Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine (TA19)
This guidance has been replaced by NICE technology appraisal guidance 111.
This guidance has been replaced by NICE technology appraisal guidance 83.